|Bid||0.00 x 900|
|Ask||0.00 x 3100|
|Day's Range||497.12 - 509.54|
|52 Week Range||328.13 - 664.64|
|Beta (5Y Monthly)||0.40|
|PE Ratio (TTM)||18.28|
|Earnings Date||Feb 04, 2021 - Feb 08, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||673.13|
With the latest purchase of 6,50,000 additional doses, the U.S. government acquires a total of 9,50,000 doses of bamlanivimab from Eli Lilly (LLY).
Scott+Scott Continues Investigation of Regeneron Pharmaceuticals, Inc.’s Directors and Officers for Breach of Fiduciary Duty – REGN
The Interfaith Center on Corporate Responsibility has filed shareholder proposals at six pharmaceutical companies.